Literature DB >> 31774311

Evaluation of the epidemiology of peanut allergy in the United Kingdom.

Laura A Scott1, Bethan I Jones1, Thomas R Berni1, Ellen R Berni1, Jane De Vries2, Craig J Currie1,3.   

Abstract

Aims: To describe the epidemiology of peanut allergy (PA) in the UK over the last three decades.
Methods: PA patients were identified from the Clinical Practice Research Datalink between 1987 and 2015. Incidence and prevalence of PA were compared between 2000 and 2015. Prevalence and relative risk (RR) of atopic comorbidities, anaphylaxis, adrenaline prescriptions versus matched controls were calculated.
Results: Point prevalence of PA in the entire population and those <18 years increased from 31 to 202 and 116 to 635 per 100,000, respectively, between 2000 and 2015. Incidence increased from 8.6 to 18.2 per 100,000. Incidence in 2015 was 105 cases per 100,000 aged 0-4 years versus 13.4 per 100,000 aged 5+ years. Anaphylactic events affected 1.2% of the cases and 0.007% of the controls. The rate of adrenaline prescriptions was 5,910 per 100,000 person-years for PA patients. RRs for asthma, eczema and allergic rhinitis in PA patients versus controls were 4.5 (95% CI 4.2-4.8), 3.2 (3.1-3.4) and 2.6 (2.4-3.0), respectively.Conclusions: The prevalence and incidence of PA increased markedly over the study period. PA was associated with atopic conditions and anaphylaxis. PA patients had increased adrenaline prescriptions.

Entities:  

Keywords:  Peanut; allergy; anaphylaxis; atopy; epidemiology

Mesh:

Substances:

Year:  2019        PMID: 31774311     DOI: 10.1080/1744666X.2020.1693264

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  4 in total

1.  Exploring Health-Related Quality of Life Burden in Peanut Allergy and the Potential Benefit of Oral Immunotherapy: Estimation of Health State Utility Values for Children and Adolescents and Their Caregivers.

Authors:  Katy Gallop; Sarah Acaster; Jane de Vries; Richard Browne; Robert Ryan; Sarah Baker; George Du Toit
Journal:  Patient Prefer Adherence       Date:  2022-05-20       Impact factor: 2.314

Review 2.  Oral immunotherapy for peanut allergy: The con argument.

Authors:  Alessandro Fiocchi; Maria Cristina Artesani; Vincenzo Fierro; Carla Riccardi; Lamia Dahdah; Maurizio Mennini
Journal:  World Allergy Organ J       Date:  2020-09-18       Impact factor: 4.084

Review 3.  Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented?

Authors:  Helen A Brough; Kari C Nadeau; Sayantani B Sindher; Shifaa S Alkotob; Susan Chan; Henry T Bahnson; Donald Y M Leung; Gideon Lack
Journal:  Allergy       Date:  2020-05-18       Impact factor: 13.146

4.  Peanut components measured by ISAC: comparison with ImmunoCap and clinical relevance in peanut allergic children.

Authors:  H K Brand; M W J Schreurs; J A M Emons; R Gerth van Wijk; H de Groot; N J T Arends
Journal:  Clin Mol Allergy       Date:  2021-08-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.